Remove 2025 Remove Documentation Remove Immunization Remove Labelling
article thumbnail

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

PharmaShots

We are conducting an open-label, dose-escalation, phase I/II study PDC-LUNG-101 assessing the safety, tolerability, immunogenicity, and the preliminary clinical activity of therapeutic cancer vaccine PDC*lung, associated or not with anti-PD1 treatment in patients with non-small-cell lung cancer (NSCLC). 2015; Zhu et al., 2015; Zhu et al.,

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

A typical individual EHR may include a patient’s medical history, diagnoses, treatment plans, immunization dates, allergies, radiology images, pharmacy records, and laboratory and test results. Global Strategy on Digital Health 2020-2025.” General wellness apps. Is the product “software” according to the definition of MDCG 2019-11?

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

A typical individual EHR may include a patient’s medical history, diagnoses, treatment plans, immunization dates, allergies, radiology images, pharmacy records, and laboratory and test results. Global Strategy on Digital Health 2020-2025.” General wellness apps. Is the product “software” according to the definition of MDCG 2019-11?